HMGB1 and infection: Therapeutic efficacy initially demonstrated for mouse-adapted influenza strains and later in cotton rats challenged with non-adapted human influenza strains; blocks release of HMGB1 and cytokines (24, 25). Later, Eritoran demonstrated therapeutic efficacy against infection with EBOV (79)